At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 69 enrolled
Drug / intervention
PERSERIS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of 180 mg Risperidone Subcutaneous Injection (PERSERIS) Following a Switch From 6 mg Oral Risperidone in Patients With Clinically Stable Schizophrenia
In Brief
A Phase 4 clinical trial evaluating PERSERIS and Risperidone for Schizophrenia. Completed, enrolled 69 participants across 1 site.
Detailed Summary
This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose, which is believed to be similar to the oral dose
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJun 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedJun 7, 2019
Enrollment StartJun 28, 2019
Primary CompletionMay 12, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.1 years ago
Interventions
PERSERISdrug
PERSERIS is an extended-release SC injectable suspension administered once-monthly
Risperidonedrug
Oral risperidone